Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

PMID:
22845873
[PubMed - indexed for MEDLINE]
2.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

Thompson JL.

Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8. Review.

PMID:
23300152
[PubMed - indexed for MEDLINE]
3.

Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.

McCormack PL.

Drugs. 2012 Oct 22;72(15):2023-32. doi: 10.2165/11209010-000000000-00000. Review.

PMID:
22994535
[PubMed - indexed for MEDLINE]
4.

Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.

Steele JM.

J Oncol Pharm Pract. 2013 Dec;19(4):348-54. doi: 10.1177/1078155212470388. Epub 2013 Jan 4. Review.

PMID:
23292972
[PubMed - indexed for MEDLINE]
5.

Bortezomib: a review of its use in patients with multiple myeloma.

Curran MP, McKeage K.

Drugs. 2009;69(7):859-88. doi: 10.2165/00003495-200969070-00006. Review.

PMID:
19441872
[PubMed - indexed for MEDLINE]
6.

Proteasome inhibitors in the treatment of multiple myeloma.

Shah JJ, Orlowski RZ.

Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10. Review.

PMID:
19741722
[PubMed - indexed for MEDLINE]
7.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
[PubMed - indexed for MEDLINE]
8.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
[PubMed - indexed for MEDLINE]
9.

Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.

Martin TG.

Oncology (Williston Park). 2013 Dec;27 Suppl 3:4-10. Review.

PMID:
25184230
[PubMed - indexed for MEDLINE]
Free Article
10.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
[PubMed - indexed for MEDLINE]
11.

Carfilzomib: a novel agent for multiple myeloma.

Redic K.

J Pharm Pharmacol. 2013 Aug;65(8):1095-106. doi: 10.1111/jphp.12072. Epub 2013 Apr 24. Review.

PMID:
23837578
[PubMed - indexed for MEDLINE]
12.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
[PubMed - indexed for MEDLINE]
13.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
[PubMed - indexed for MEDLINE]
14.

The development of proteasome inhibitors as anticancer drugs.

Adams J.

Cancer Cell. 2004 May;5(5):417-21. Review.

PMID:
15144949
[PubMed - indexed for MEDLINE]
15.

Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Plosker GL.

Drugs. 2008;68(17):2535-51. doi: 10.2165/0003495-200868170-00008. Review.

PMID:
19016577
[PubMed - indexed for MEDLINE]
16.

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Richardson PG, Mitsiades C, Ghobrial I, Anderson K.

Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.

PMID:
16988581
[PubMed - indexed for MEDLINE]
17.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
[PubMed - indexed for MEDLINE]
18.

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

Jakubowiak AJ.

Cancer Treat Rev. 2014 Jul;40(6):781-90. doi: 10.1016/j.ctrv.2014.02.005. Epub 2014 Mar 1. Review.

PMID:
24630735
[PubMed - indexed for MEDLINE]
Free Article
19.

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

Cavo M.

Leukemia. 2006 Aug;20(8):1341-52. Epub 2006 Jun 29. Review.

PMID:
16810203
[PubMed - indexed for MEDLINE]
20.

A practical update on the use of bortezomib in the management of multiple myeloma.

San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H.

Oncologist. 2006 Jan;11(1):51-61. Review.

PMID:
16401713
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk